In addition, the use of KDs for prolonged periods, as in GLUT1-DS patients and in patients with metabolic diseases, requires foods with a lipid profile characterized by a greater presence of MUFA and PUFA and lower in SFA; this is in order to reduce the risk of future dyslipidemia and cardiovascular problems. This evidence concerns the gene SLC2A1 and metabolic syndrome.